A Phase 1 interventional study of Pirtobrutinib in Healthy and Hepatic Insufficiency, sponsored by Eli Lilly and Company. Completed at 8 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-09.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Hepatic Insufficiency by Eli Lilly and Company — 2 open to participants now, 2 under way, none of them phase 3. Hepatic Insufficiency · Eli Lilly and Company.
Among the 12 studies in Hepatic Insufficiency by Eli Lilly and Company, this one is the 3rd largest by enrollment, is the only one that started in 2020, is one of 12 in phase 1, and was the 9th registered.
113 studies on the registry are indexed under Hepatic Insufficiency; 15 are open to participants now.
Browse Hepatic Insufficiency studies →2 of the 12 studies in Hepatic Insufficiency by Eli Lilly and Company are open now, in 4 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Hungary
Ages 18–85 · Healthy volunteers
Eli Lilly and Company · Sites in Hungary, New Zealand, Slovakia
Ages 18–85 · Healthy volunteers
By country, each count listing its studies:
Of the 9 Hepatic Insufficiency studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is above the median of 29 across 100 interventional studies indexed under Hepatic Insufficiency.
Median enrollment 34 across the 12 interventional studies. Of the 10 that completed or were terminated, 8 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
2 of the studies in Hepatic Insufficiency by Eli Lilly and Company that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07165002Eli Lilly and CompanyA Study of the Pharmacokinetics and Safety of LY3537031 in Participants With Normal Liver Function and With Mild, Moderate, or Severe Liver Impairment | 2026-11 |
| NCT07401862Eli Lilly and CompanyA Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers. | 2027-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies in Hepatic Insufficiency by Eli Lilly and Company, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to measure how much of pirtobrutinib (LOXO-305) gets into the bloodstream and how long it takes the body to eliminate it in participants with impaired liver function and healthy participants. The side effects and tolerability of pirtobrutinib will also be evaluated. Participation could last about 46 days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
History or presence of any of the following, deemed by the Investigator (or designee), and/or Sponsor:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a single dose of Pirtobrutinib 200 milligrams (mg) administered orally on Day 1.
Drug: Pirtobrutinib
Participants received a single dose of Pirtobrutinib 200 mg administered orally on Day 1.
Drug: Pirtobrutinib
Participants received a single dose of Pirtobrutinib 200 mg administered orally on Day 1.
Drug: Pirtobrutinib
Participants received a single dose of Pirtobrutinib 200 mg administered orally on Day 1.
Drug: Pirtobrutinib
Administered orally
Also known as: LOXO-305, LY3527727
Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Pirtobrutinib
PK: Cmax of pirtobrutinib
Time frame: Day 1 (predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose)
PK: Time to Maximum Observed Plasma Concentration (Tmax) of Pirtobrutinib
PK: Tmax of pirtobrutinib
Time frame: Day 1 (predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose)
PK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) of Pirtobrutinib
PK: AUC0-t of pirtobrutinib
Time frame: Day 1 (predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose)
PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of Pirtobrutinib
PK: AUC0-inf of pirtobrutinib
Time frame: Day 1 (predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose)
PK: Percentage Extrapolation for AUC0-inf (%AUCextrap) of Pirtobrutinib
PK: %AUCextrap of pirtobrutinib
Time frame: Day 1 (predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose)
PK: Apparent Plasma Terminal Elimination Half-life (t½) of Pirtobrutinib
PK: t½ of pirtobrutinib
Time frame: Day 1 (predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose)
PK: Apparent Systemic Clearance (CL/F) of Pirtobrutinib
PK: CL/F of pirtobrutinib
Time frame: Day 1 (predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose)
PK: Apparent Volume of Distribution During the Terminal Phase (Vz/F) of Pirtobrutinib
PK: Vz/F of pirtobrutinib
Time frame: Day 1 (predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose)
PK: Mean Residence Time (MRT) of Pirtobrutinib
MRT is the average time a drug molecule stays in the body, calculated from the AUC0-inf.
Time frame: Day 1 (predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose)
PK: Unbound Cmax (Cmax,u) of Pirtobrutinib
Cmax,u was calculated by multiplying Cmax by Fu (i.e., Cmax\*Fu). Fu represents the unbound fraction, which is the portion of the drug in the bloodstream that is unbound to plasma proteins. It is expressed as a decimal and will be calculated from protein binding concentration data as the unbound drug concentration divided by the total drug concentration in plasma. The concentrations of total and unbound drug were determined in a sample of predose plasma fortified with a known concentration of drug.
Time frame: Day 1 (predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose)
PK: Unbound AUC0-t (AUC0-t,u) of Pirtobrutinib
AUC0-t,u was calculated by multiplying AUC0-t by Fu (i.e., AUC0-t\*Fu). Fu represents the unbound fraction, which is the portion of the drug in the bloodstream that is unbound to plasma proteins. It is expressed as a decimal and will be calculated from protein binding concentration data as the unbound drug concentration divided by the total drug concentration in plasma. The concentrations of total and unbound drug were determined in a sample of predose plasma fortified with a known concentration of drug.
Time frame: Day 1 (predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose)
PK: Unbound AUC0-inf (AUC0-inf,u) of Pirtobrutinib
AUC0-inf,u was calculated by multiplying AUC0-inf by Fu (i.e., AUC0-inf\*Fu). Fu represents the unbound fraction, which is the portion of the drug in the bloodstream that is unbound to plasma proteins. It is expressed as a decimal and will be calculated from protein binding concentration data as the unbound drug concentration divided by the total drug concentration in plasma. The concentrations of total and unbound drug were determined in a sample of predose plasma fortified with a known concentration of drug.
Time frame: Day 1 (predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose)
PK: Unbound CL/F (CL/F,u) of Pirtobrutinib
CL/F,u was calculated by multiplying CL/F by Fu (i.e., CL/F\*Fu). Fu represents the unbound fraction, which is the portion of the drug in the bloodstream that is unbound to plasma proteins. It is expressed as a decimal and will be calculated from protein binding concentration data as the unbound drug concentration divided by the total drug concentration in plasma. The concentrations of total and unbound drug were determined in a sample of predose plasma fortified with a known concentration of drug.
Time frame: Day 1 (predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose)
PK: Unbound Vz/F (Vz/F,u) of Pirtobrutinib
Vz/F,u was calculated by multiplying Vz/F by Fu (i.e., Vz/F\*Fu). Fu represents the unbound fraction, which is the portion of the drug in the bloodstream that is unbound to plasma proteins. It is expressed as a decimal and will be calculated from protein binding concentration data as the unbound drug concentration divided by the total drug concentration in plasma. The concentrations of total and unbound drug were determined in a sample of predose plasma fortified with a known concentration of drug.
Time frame: Day 1 (predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose)
PK: Apparent Terminal Elimination Rate Constant (λZ) of Pirtobrutinib (Normal Hepatic Function)
PK: λZ of pirtobrutinib
Time frame: Day 1 (predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose)
PK: Apparent Terminal Elimination Rate Constant (λZ) of Pirtobrutinib (Mild Hepatic Function)
PK: λZ of pirtobrutinib
Time frame: Day 1 (predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose)
PK: Apparent Terminal Elimination Rate Constant (λZ) of Pirtobrutinib (Moderate Hepatic Function)
PK: λZ of pirtobrutinib
Time frame: Day 1 (predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose)
PK: Apparent Terminal Elimination Rate Constant (λZ) of Pirtobrutinib (Severe Hepatic Function)
PK: λZ of pirtobrutinib
Time frame: Day 1 (predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose)
| Milestone | Pirtobrutinib (Normal Hepatic Function) | Pirtobrutinib (Mild Hepatic Impairment) | Pirtobrutinib (Moderate Hepatic Impairment) | Pirtobrutinib (Severe Hepatic Impairment) |
|---|---|---|---|---|
| Started | 14 | 8 | 8 | 6 |
| Received dose of pirtobrutinib | 14 | 8 | 8 | 6 |
| Completed | 12 | 8 | 8 | 6 |
| Not completed | 2 | 0 | 0 | 0 |
| Withdrew: Adverse event | 2 | 0 | 0 | 0 |
PK: Cmax of pirtobrutinib
| nanogram per milliliter (ng/mL) | Pirtobrutinib (Normal Hepatic Function) | Pirtobrutinib (Mild Hepatic Impairment) | Pirtobrutinib (Moderate Hepatic Impairment) | Pirtobrutinib (Severe Hepatic Impairment) |
|---|---|---|---|---|
| Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Pirtobrutinib | 4240 ± 32.4 | 4410 ± 22.7 | 4140 ± 20.8 | 3270 ± 22.8 |
PK: Tmax of pirtobrutinib
| hours | Pirtobrutinib (Normal Hepatic Function) | Pirtobrutinib (Mild Hepatic Impairment) | Pirtobrutinib (Moderate Hepatic Impairment) | Pirtobrutinib (Severe Hepatic Impairment) |
|---|---|---|---|---|
| PK: Time to Maximum Observed Plasma Concentration (Tmax) of Pirtobrutinib | 2.50 (1 to 8) | 2.25 (1 to 6) | 2.25 (1 to 3) | 2.78 (2 to 4) |
PK: AUC0-t of pirtobrutinib
| hour*nanogram per milliliter (h*ng/mL) | Pirtobrutinib (Normal Hepatic Function) | Pirtobrutinib (Mild Hepatic Impairment) | Pirtobrutinib (Moderate Hepatic Impairment) | Pirtobrutinib (Severe Hepatic Impairment) |
|---|---|---|---|---|
| PK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) of Pirtobrutinib | 96800 ± 21.2 | 89900 ± 43 | 84600 ± 31.7 | 71500 ± 14.8 |
PK: AUC0-inf of pirtobrutinib
| hour*nanogram per milliliter (h*ng/mL) | Pirtobrutinib (Normal Hepatic Function) | Pirtobrutinib (Mild Hepatic Impairment) | Pirtobrutinib (Moderate Hepatic Impairment) | Pirtobrutinib (Severe Hepatic Impairment) |
|---|---|---|---|---|
| PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of Pirtobrutinib | 98000 ± 20.7 | 90900 ± 42.7 | 85700 ± 31.1 | 72200 ± 14.6 |
PK: %AUCextrap of pirtobrutinib
| percentage of AUCextrap | Pirtobrutinib (Normal Hepatic Function) | Pirtobrutinib (Mild Hepatic Impairment) | Pirtobrutinib (Moderate Hepatic Impairment) | Pirtobrutinib (Severe Hepatic Impairment) |
|---|---|---|---|---|
| PK: Percentage Extrapolation for AUC0-inf (%AUCextrap) of Pirtobrutinib | 0.978 ± 67.3 | 1.13 ± 34.4 | 1.14 ± 54.7 | 0.921 ± 50.4 |
PK: t½ of pirtobrutinib
| hours | Pirtobrutinib (Normal Hepatic Function) | Pirtobrutinib (Mild Hepatic Impairment) | Pirtobrutinib (Moderate Hepatic Impairment) | Pirtobrutinib (Severe Hepatic Impairment) |
|---|---|---|---|---|
| PK: Apparent Plasma Terminal Elimination Half-life (t½) of Pirtobrutinib | 21.2 ± 20.9 | 19.8 ± 27.7 | 18 ± 16.3 | 15.5 ± 26.6 |
PK: CL/F of pirtobrutinib
| liter per hour (L/h) | Pirtobrutinib (Normal Hepatic Function) | Pirtobrutinib (Mild Hepatic Impairment) | Pirtobrutinib (Moderate Hepatic Impairment) | Pirtobrutinib (Severe Hepatic Impairment) |
|---|---|---|---|---|
| PK: Apparent Systemic Clearance (CL/F) of Pirtobrutinib | 2.04 ± 20.7 | 2.20 ± 42.7 | 2.33 ± 31.1 | 2.77 ± 14.6 |
PK: Vz/F of pirtobrutinib
| Liter (L) | Pirtobrutinib (Normal Hepatic Function) | Pirtobrutinib (Mild Hepatic Impairment) | Pirtobrutinib (Moderate Hepatic Impairment) | Pirtobrutinib (Severe Hepatic Impairment) |
|---|---|---|---|---|
| PK: Apparent Volume of Distribution During the Terminal Phase (Vz/F) of Pirtobrutinib | 62.4 ± 29.5 | 62.9 ± 45.1 | 60.6 ± 30.1 | 61.8 ± 30.5 |
MRT is the average time a drug molecule stays in the body, calculated from the AUC0-inf.
| hours | Pirtobrutinib (Normal Hepatic Function) | Pirtobrutinib (Mild Hepatic Impairment) | Pirtobrutinib (Moderate Hepatic Impairment) | Pirtobrutinib (Severe Hepatic Impairment) |
|---|---|---|---|---|
| PK: Mean Residence Time (MRT) of Pirtobrutinib | 28.8 ± 17.6 | 27.7 ± 26.3 | 25 ± 14 | 24 ± 26.2 |
Cmax,u was calculated by multiplying Cmax by Fu (i.e., Cmax\*Fu). Fu represents the unbound fraction, which is the portion of the drug in the bloodstream that is unbound to plasma proteins. It is expressed as a decimal and will be calculated from protein binding concentration data as the unbound drug concentration divided by the total drug concentration in plasma. The concentrations of total and unbound drug were determined in a sample of predose plasma fortified with a known concentration of drug.
| nanogram per milliliter (ng/mL) | Pirtobrutinib (Normal Hepatic Function) | Pirtobrutinib (Mild Hepatic Impairment) | Pirtobrutinib (Moderate Hepatic Impairment) | Pirtobrutinib (Severe Hepatic Impairment) |
|---|---|---|---|---|
| PK: Unbound Cmax (Cmax,u) of Pirtobrutinib | 107 ± 31.2 | 133 ± 16.3 | 118 ± 26.5 | 111 ± 27.5 |
AUC0-t,u was calculated by multiplying AUC0-t by Fu (i.e., AUC0-t\*Fu). Fu represents the unbound fraction, which is the portion of the drug in the bloodstream that is unbound to plasma proteins. It is expressed as a decimal and will be calculated from protein binding concentration data as the unbound drug concentration divided by the total drug concentration in plasma. The concentrations of total and unbound drug were determined in a sample of predose plasma fortified with a known concentration of drug.
| hour*nanogram per milliliter (h*ng/mL) | Pirtobrutinib (Normal Hepatic Function) | Pirtobrutinib (Mild Hepatic Impairment) | Pirtobrutinib (Moderate Hepatic Impairment) | Pirtobrutinib (Severe Hepatic Impairment) |
|---|---|---|---|---|
| PK: Unbound AUC0-t (AUC0-t,u) of Pirtobrutinib | 2440 ± 22.8 | 2710 ± 32.3 | 2410 ± 39.6 | 2410 ± 28.5 |
AUC0-inf,u was calculated by multiplying AUC0-inf by Fu (i.e., AUC0-inf\*Fu). Fu represents the unbound fraction, which is the portion of the drug in the bloodstream that is unbound to plasma proteins. It is expressed as a decimal and will be calculated from protein binding concentration data as the unbound drug concentration divided by the total drug concentration in plasma. The concentrations of total and unbound drug were determined in a sample of predose plasma fortified with a known concentration of drug.
| hour*nanogram per milliliter (h*ng/mL) | Pirtobrutinib (Normal Hepatic Function) | Pirtobrutinib (Mild Hepatic Impairment) | Pirtobrutinib (Moderate Hepatic Impairment) | Pirtobrutinib (Severe Hepatic Impairment) |
|---|---|---|---|---|
| PK: Unbound AUC0-inf (AUC0-inf,u) of Pirtobrutinib | 2470 ± 22.6 | 2740 ± 32.1 | 2440 ± 39.1 | 2440 ± 28.5 |
CL/F,u was calculated by multiplying CL/F by Fu (i.e., CL/F\*Fu). Fu represents the unbound fraction, which is the portion of the drug in the bloodstream that is unbound to plasma proteins. It is expressed as a decimal and will be calculated from protein binding concentration data as the unbound drug concentration divided by the total drug concentration in plasma. The concentrations of total and unbound drug were determined in a sample of predose plasma fortified with a known concentration of drug.
| liter per hour (L/h) | Pirtobrutinib (Normal Hepatic Function) | Pirtobrutinib (Mild Hepatic Impairment) | Pirtobrutinib (Moderate Hepatic Impairment) | Pirtobrutinib (Severe Hepatic Impairment) |
|---|---|---|---|---|
| PK: Unbound CL/F (CL/F,u) of Pirtobrutinib | 80.9 ± 22.6 | 73 ± 32.1 | 81.9 ± 39.1 | 82 ± 28.5 |
Vz/F,u was calculated by multiplying Vz/F by Fu (i.e., Vz/F\*Fu). Fu represents the unbound fraction, which is the portion of the drug in the bloodstream that is unbound to plasma proteins. It is expressed as a decimal and will be calculated from protein binding concentration data as the unbound drug concentration divided by the total drug concentration in plasma. The concentrations of total and unbound drug were determined in a sample of predose plasma fortified with a known concentration of drug.
| Liter (L) | Pirtobrutinib (Normal Hepatic Function) | Pirtobrutinib (Mild Hepatic Impairment) | Pirtobrutinib (Moderate Hepatic Impairment) | Pirtobrutinib (Severe Hepatic Impairment) |
|---|---|---|---|---|
| PK: Unbound Vz/F (Vz/F,u) of Pirtobrutinib | 2470 ± 26 | 2090 ± 34 | 2130 ± 33.1 | 1830 ± 36.3 |
PK: λZ of pirtobrutinib
| 1/hour (1/h) | Pirtobrutinib (Normal Hepatic Function) |
|---|---|
| Subject 1 | 0.0334 |
| Subject 2 | 0.0323 |
| Subject 3 | 0.0418 |
| Subject 4 | 0.0287 |
| Subject 5 | 0.0231 |
| Subject 6 | 0.0319 |
| Subject 7 | 0.0420 |
| Subject 8 | 0.0262 |
| Subject 9 | 0.0292 |
| Subject 10 | 0.0291 |
| Subject 11 | 0.0299 |
| Subject 12 | 0.0308 |
| Subject 13 | 0.0399 |
| Subject 14 | 0.0491 |
PK: λZ of pirtobrutinib
| 1/hour (1/h) | Pirtobrutinib (Mild Hepatic Impairment) |
|---|---|
| Subject 15 | 0.0270 |
| Subject 16 | 0.0448 |
| Subject 17 | 0.0453 |
| Subject 18 | 0.0336 |
| Subject 19 | 0.0234 |
| Subject 20 | 0.0273 |
| Subject 21 | 0.0432 |
| Subject 22 | 0.0440 |
PK: λZ of pirtobrutinib
| 1/hour (1/h) | Pirtobrutinib (Moderate Hepatic Impairment) |
|---|---|
| Subject 23 | 0.0377 |
| Subject 24 | 0.0387 |
| Subject 25 | 0.0364 |
| Subject 26 | 0.0430 |
| Subject 27 | 0.0395 |
| Subject 28 | 0.0467 |
| Subject 29 | 0.0419 |
| Subject 30 | 0.0272 |
PK: λZ of pirtobrutinib
| 1/hour (1/h) | Pirtobrutinib (Severe Hepatic Impairment) |
|---|---|
| Subject 31 | 0.0401 |
| Subject 32 | 0.0526 |
| Subject 33 | 0.0279 |
| Subject 34 | 0.0522 |
| Subject 35 | 0.0465 |
| Subject 36 | 0.0567 |
Collected over Baseline to Follow-up (Up To Day 17). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pirtobrutinib (Normal Hepatic Function) | 0/14 (0%) | 0/14 (0%) | 3/14 (21.4%) |
| Pirtobrutinib (Mild Hepatic Impairment) | 0/8 (0%) | 0/8 (0%) | 2/8 (25%) |
| Pirtobrutinib (Moderate Hepatic Impairment) | 0/8 (0%) | 0/8 (0%) | 0/8 (0%) |
| Pirtobrutinib (Severe Hepatic Impairment) | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Event | Pirtobrutinib (Normal Hepatic Function) | Pirtobrutinib (Mild Hepatic Impairment) | Pirtobrutinib (Moderate Hepatic Impairment) | Pirtobrutinib (Severe Hepatic Impairment) |
|---|---|---|---|---|
| ConstipationGastrointestinal disorders | 0/14 | 1/8 | 0/8 | 1/6 |
| SARS-CoV-2 test positiveInvestigations | 2/14 | 0/8 | 0/8 | 0/6 |
| HeadacheNervous system disorders | 0/14 | 1/8 | 0/8 | 0/6 |
| DiarrhoeaGastrointestinal disorders | 1/14 | 0/8 | 0/8 | 0/6 |
All enrolled participants.
| Age, Continuous(years) | Pirtobrutinib (Normal Hepatic Function) | Pirtobrutinib (Mild Hepatic Impairment) | Pirtobrutinib (Moderate Hepatic Impairment) | Pirtobrutinib (Severe Hepatic Impairment) | Total |
|---|---|---|---|---|---|
| Mean | 54.4 ± 8.22 | 56.8 ± 4.560 | 56.3 ± 3.920 | 52.3 ± 9.350 | 55 ± 6.880 |
| Sex: Female, Male(Participants) | Pirtobrutinib (Normal Hepatic Function) | Pirtobrutinib (Mild Hepatic Impairment) | Pirtobrutinib (Moderate Hepatic Impairment) | Pirtobrutinib (Severe Hepatic Impairment) | Total |
|---|---|---|---|---|---|
| Female | 4 | 3 | 2 | 1 | 10 |
| Male | 10 | 5 | 6 | 5 | 26 |
| Ethnicity (NIH/OMB)(Participants) | Pirtobrutinib (Normal Hepatic Function) | Pirtobrutinib (Mild Hepatic Impairment) | Pirtobrutinib (Moderate Hepatic Impairment) | Pirtobrutinib (Severe Hepatic Impairment) | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 5 | 5 | 4 | 5 | 19 |
| Not Hispanic or Latino | 9 | 3 | 4 | 1 | 17 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Pirtobrutinib (Normal Hepatic Function) | Pirtobrutinib (Mild Hepatic Impairment) | Pirtobrutinib (Moderate Hepatic Impairment) | Pirtobrutinib (Severe Hepatic Impairment) | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 3 | 2 | 0 | 0 | 5 |
| White | 11 | 6 | 8 | 6 | 31 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Pirtobrutinib (Normal Hepatic Function) | Pirtobrutinib (Mild Hepatic Impairment) | Pirtobrutinib (Moderate Hepatic Impairment) | Pirtobrutinib (Severe Hepatic Impairment) | Total |
|---|---|---|---|---|---|
| United States | 14 | 8 | 8 | 6 | 36 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2020 to primary completion in Dec 2021, 12 months.
Results were first posted in Jan 2025, 3 years after primary completion.
Of 38 industry-sponsored phase 1 interventional studies under Hepatic Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 17. This study's 12 months is above that.
Counting every sponsor, half of 41 studies reached it within 8 months; a quarter within 5 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pirtobrutinib